BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

Completed · Phase 1

Conditions studied: Colorectal Cancer

In brief

This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.

Key facts

Study ID

NCT00207051

Run by

Bristol-Myers Squibb

People needed

62

Starts

2006-01-01

Expected to finish

2008-12-01

Last updated by the study team

2011-01-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of advanced or metastatic (tumor has spread) gastrointestinal malignancy
• Feeling well other than cancer diagnosis (ie lab work, no infection, etc)
• Available tumor tissue sample from prior surgery
• Measurable disease on scans
• 4-6 weeks since prior therapy and recovered from the effects of prior therapy
• Men and women, ages 18 and above
• Women must not be pregnant or breastfeeding

Where it is running

• Usc/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Georgetn Univ Lombardi Can Ctr — Washington D.C., District of Columbia, United States
• University Of Miami Miller School Of Medicine — Miami, Florida, United States
• H. Lee Moffitt Cancer Center — Tampa, Florida, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Local Institution — Hamilton, Ontario, Canada
• Local Institution — Toronto, Ontario, Canada
• Local Institution — Amsterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.